Farletuzumab ecteribulin
Product Sizes
5 mg
£ POA
HY-P99612-5MG
10 mg
£ POA
HY-P99612-10MG
1 mg
£ POA
HY-P99612-1MG
About this Product
- SKU:
- HY-P99612
- Additional Names:
- MORAb-202
- Application:
- Antibody Microarray
- CAS Number:
- 2407465-18-1
- Extra Details:
- Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC); consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
- Molecular Weight:
- 149000 (average)
- Purity:
- 99.40
- References:
- [1]Keiji Furuuchi, et al. Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models. Cancer Sci. 2021 Jun;112(6):2467-2480.|[2]Xin Cheng, et al. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Mol Cancer Ther. 2018 Dec;17(12):2665-2675.
- Research Area:
- Cancer
- Shipping Conditions:
- Dry Ice
- Storage Conditions:
- -80[o]C; protect from light
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Conjugated Protein
- Pathway:
- Antibody-drug Conjugate/ADC Related
